Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975438 · ClinicalTrials.gov registry record · Phase 1
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04975438 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 34 participants.
The verdict
NCT04975438, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
Interventions
- DRUG Placebo
- DRUG GSK1070806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2023-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975438
The ClinicalTrials.gov registry entry for NCT04975438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04975438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04975438 about?
NCT04975438 is a clinical study titled "Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis". This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
What is the current status of trial NCT04975438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-11-18. Estimated completion is 2023-03-13.
What interventions are being tested in trial NCT04975438?
The interventions under investigation include: Placebo (DRUG), GSK1070806 (DRUG).
Who is sponsoring clinical trial NCT04975438?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.